Galectin Therapeutics Inc. (GALT)

[biotech2010]

I would really encourage all GALT shareholders to carefully review the interim psoriasis data and compare it to the discussion of another psoriasis trial at this link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2504074/

The next set of results, after the extension of the treatments, could easily show the achievement of the necessary endpoint (PASI 75 on 70-80% of the patients) that would make this a real candidate for a Phase 3 trial for approval (and a potential partnership with a big Pharma for commercialization).

This, in my opinion, is the most significant positive step forward in the long (and sometimes turbulent) history of GALT.